Mast Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mast Therapeutics, Inc.
Having licensed rights to Movantik from AstraZeneca in February, RedHill has now offloaded EU rights to Cosmo. Calliditas to obtain PBC candidate in bid to acquire Genkyotex.
Deal Snapshot: In acquiring its fellow San Diego firm for an estimated deal value of up to $516m, Ligand picks up protein-expression technology, revenue-driving partnerships and the potential for more.
Ligand Pharmaceuticals has struck a deal to acquire Pfenex in a transaction valued at up to $516m.
Pfenex has less than two months for an “A” designation for therapeutic equivalence for to be granted for its Bonsity (teriparatide) 505(b)(2) product by the US FDA if it wishes to realize maximum value under the companies’ partnership agreement with Alvogen.
- Other Names / Subsidiaries
- Adventrx Pharmaceuticals, Inc.
- Aires Pharmaceuticals, Inc.
- SynthRx, Inc.